Total Payments
$486,886
2024 Payments
$53,018
Companies
15
Transactions
170
Medicare Patients
136
Medicare Billing
$18,343
Payment Breakdown by Category
Consulting$282,446 (58.0%)
Research$180,611 (37.1%)
Travel$12,248 (2.5%)
Other$7,780 (1.6%)
Food & Beverage$3,802 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $282,446 | 64 | 58.0% |
| Unspecified | $180,611 | 7 | 37.1% |
| Travel and Lodging | $12,248 | 35 | 2.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,780 | 3 | 1.6% |
| Food and Beverage | $3,802 | 61 | 0.8% |
Payments by Type
General
$306,276
163 transactions
Research
$180,611
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $344,160 | 73 | $0 (2024) |
| Eisai Inc. | $82,765 | 38 | $0 (2024) |
| Lilly USA, LLC | $30,860 | 21 | $0 (2024) |
| ROCHE MOLECULAR SYSTEMS, INC. | $10,004 | 2 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $8,717 | 6 | $0 (2022) |
| GE HEALTHCARE | $4,939 | 10 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $2,141 | 4 | $0 (2023) |
| Eli Lilly and Company | $1,297 | 3 | $0 (2024) |
| ROCHE DIAGNOSTICS INTERNATIONAL LTD | $1,180 | 1 | $0 (2022) |
| Janssen Research & Development, LLC | $478.13 | 6 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $53,018 | 39 | Biogen, Inc. ($14,121) |
| 2023 | $30,697 | 25 | Eisai Inc. ($15,615) |
| 2022 | $84,249 | 32 | EISAI INC. ($38,205) |
| 2021 | $82,794 | 17 | Biogen, Inc. ($82,254) |
| 2020 | $15,179 | 8 | Biogen, Inc. ($15,179) |
| 2019 | $52,000 | 3 | Biogen, Inc. ($34,000) |
| 2018 | $123,130 | 13 | Biogen, Inc. ($122,977) |
| 2017 | $45,818 | 33 | Biogen, Inc. ($39,807) |
All Payment Transactions
170 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,795.00 | General |
| 12/17/2024 | Biogen, Inc. | — | Travel and Lodging | In-kind items and services | $2,055.00 | General |
| 12/17/2024 | Biogen, Inc. | — | Travel and Lodging | In-kind items and services | $373.23 | General |
| 11/23/2024 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $24.65 | General |
| 11/23/2024 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $22.99 | General |
| 11/07/2024 | Eli Lilly and Company | KISUNLA (Drug) | Consulting Fee | Cash or cash equivalent | $625.00 | General |
| Category: Neuroscience | ||||||
| 10/29/2024 | Beckman Coulter, Inc. | ACCESS 2 (Device) | Food and Beverage | In-kind items and services | $46.07 | General |
| Category: Devices | ||||||
| 10/23/2024 | Eisai Inc. | Leqembi (Drug) | Consulting Fee | Cash or cash equivalent | $1,755.00 | General |
| Category: Neurology | ||||||
| 10/02/2024 | Eisai Inc. | Leqembi (Drug) | Consulting Fee | Cash or cash equivalent | $3,510.00 | General |
| Category: Neurology | ||||||
| 09/04/2024 | Eisai Inc. | Leqembi (Drug) | Consulting Fee | Cash or cash equivalent | $1,755.00 | General |
| Category: Neurology | ||||||
| 08/08/2024 | ROCHE MOLECULAR SYSTEMS, INC. | — | Consulting Fee | Cash or cash equivalent | $3,591.00 | General |
| 08/08/2024 | Eisai Inc. | Leqembi (Drug) | Consulting Fee | Cash or cash equivalent | $438.75 | General |
| Category: Neurology | ||||||
| 08/01/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $121.78 | General |
| Category: Neurology | ||||||
| 08/01/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $68.34 | General |
| Category: Neurology | ||||||
| 08/01/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $39.76 | General |
| Category: Neurology | ||||||
| 08/01/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $23.61 | General |
| Category: Neurology | ||||||
| 06/25/2024 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $6,850.00 | General |
| 06/18/2024 | GE HEALTHCARE | — | Food and Beverage | In-kind items and services | $68.79 | General |
| 05/21/2024 | Lilly USA, LLC | — | Consulting Fee | Cash or cash equivalent | $8,750.00 | General |
| 05/21/2024 | Lilly USA, LLC | — | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| 05/10/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $289.66 | General |
| 05/10/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $263.34 | General |
| 05/10/2024 | Lilly USA, LLC | KISUNLA (Drug) | Travel and Lodging | In-kind items and services | $249.00 | General |
| Category: Neuroscience | ||||||
| 05/10/2024 | Lilly USA, LLC | KISUNLA (Drug) | Travel and Lodging | In-kind items and services | $249.00 | General |
| Category: Neuroscience | ||||||
| 05/10/2024 | Lilly USA, LLC | KISUNLA (Drug) | Travel and Lodging | In-kind items and services | $249.00 | General |
| Category: Neuroscience | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Sponsored Research by J Galvin re Biologic Validation of the Quick Dementia Rating System (QDRS) as a Pre-screening instrument to increase enrollment in Alzheimer Disease clinical trials | Biogen, Inc. | $170,000 | 5 |
| International Collaboration for Real-World Evidence in Alzheimers Disease (ICARE AD) - A Prospective Real-World Observational Study of Aducanumab-avwa in Patients with Alzheimers Disease in the US. | Biogen, Inc. | $7,345 | 1 |
| Intuition: a Brain Health Study | Biogen, Inc. | $3,266 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 84 | 84 | $54,720 | $11,276 |
| 2022 | 2 | 52 | 99 | $28,170 | $7,068 |
Total Patients
136
Total Services
183
Medicare Billing
$18,343
Procedure Codes
4
All Medicare Procedures & Services
4 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 44 | 44 | $29,040 | $7,110 | 24.5% |
| 96132 | Evaluation of neuropsychological test, first hour | Office | 2023 | 40 | 40 | $25,680 | $4,166 | 16.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 29 | 29 | $19,140 | $5,159 | 27.0% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 23 | 70 | $9,030 | $1,908 | 21.1% |
About James Galvin, MD, MPH
James Galvin, MD, MPH is a Behavioral Neurology & Neuropsychiatry healthcare provider based in Boca Raton, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1760408074.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, James Galvin, MD, MPH has received a total of $486,886 in payments from pharmaceutical and medical device companies, with $53,018 received in 2024. These payments were reported across 170 transactions from 15 companies. The most common payment nature is "Consulting Fee" ($282,446).
As a Medicare-enrolled provider, Galvin has provided services to 136 Medicare beneficiaries, totaling 183 services with total Medicare billing of $18,343. Data is available for 2 years (2022–2023), covering 4 distinct procedure/service records.
Ad
Practice Information
- Specialty Behavioral Neurology & Neuropsychiatry
- Location Boca Raton, FL
- Active Since 07/14/2006
- Last Updated 10/16/2023
- Taxonomy Code 2084B0040X
- Entity Type Individual
- NPI Number 1760408074
Products in Payments
- ADUHELM (Biological) $67,980
- Leqembi (Drug) $15,529
- REXULTI (Drug) $8,717
- DaTscan (Drug) $4,400
- KISUNLA (Drug) $2,082
- Dayvigo (Drug) $540.00
- ADLARITY (Drug) $137.84
- NEURACEQ (Drug) $61.39
- ACCESS 2 (Device) $46.07
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.